Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma

Leukemia and Lymphoma

Volumn 46, Issue 8, 2005, Pages 1217-1222

  Nakashima, Yasuhiro ^a   Shiratsuchi, Motoaki ^a   Abe, Yasunobu ^b   Muta, Koichiro ^b   Tani, Kenzaburo ^a   Shiokawa, Satoshi ^a   Nishimura, Junji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Autologous hematopoietic stem cell transplantation; Graft vs myeloma effect; Multiple myeloma; Non myeloablative hematopoietic stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; QUETIAPINE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DELIRIUM; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HLA MATCHING; HUMAN; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RADIATION DOSE; SIBLING; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHIMERISM; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING;

EID: 23144463943     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500096708     Document Type: Article

References (24)

1. Tricot G. Treatment advances in multiple myeloma. Br J Haematol 2004;125:24-30.
2. Bensinger WI. Recent developments in hematopoietic stem cell transplantation for multiple myeloma. Int J Hematol 2003;77:232-238.
3. Kyle RA, Rajkumar V. Multiple myeloma. N Engl J Med 2004;351:1860-1873.
4. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-887.
5. Attal M, Harousseau JI, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Iftah N et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
6. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
7. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG, Cornelissen JJ, Schaafsma MR, van Oers HJ, Wijermans PW et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144-2151.
8. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
9. Attal M, Harousseau JL, Facon T, Gulhot F, Doyen C, Fuzibet JG, Moncondult M, Hulin C, Calliot D, Bouabdallah R et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
10. Libura J, Hoffmann T, Passweg JR, Gregor M, Fvre G, Tichelli A, Gratwohl A. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999;24:925-927.
11. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-1198.
12. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997;11:281-283.
13. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperleym J, Blade J, Carlson K, Cavo M, Ferrant A et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-4718.
14. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia effect without myeloablative therapy. Blood 1997;89:4531-4536.
15. Slavin S, Nagler A, Naperstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, AckersteinA, Samuel S et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases. Blood 1998;91:756-763.
16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA et al. Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 2001;97:3390-3400.
17. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-1303.
18. Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina. T, Fehse B, Tögel F, Wittkowsky G, Kuse R et al. Autologous stem cell transplantation followed by a dose-reduced allograft induced high complete remission rate in multiple myeloma. Blood 2002;100:755-760.
19. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sndmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454.
20. Mitterbauer M, Kalhs P, Keil F, Prinz E, Moser K, Mannhalter C, Mtterbauer G, Brugger S, Gisslinger H, Lechner K et al. Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning. Br J Haematol 2002;118:132-135.
21. Dodero A, Perfetti V, Ciceri F, Corradini P. Clinical and molecular remission following reduced intensity conditioning and allogencic transplantation in a patient with refractory multiple myeloma. Haematologica 2002;87:ECR41.
22. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-1929.
23. Mitus AJ, Stein R, Rappeport JM, Weinstein HJ, Alper CA, Smith BR. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989;75:2764-2768.
24. Nagashima T, Muroi K, Kawano-Yamamoto C, Komatsu N, Ozawa K. Paraproteinemia after hematopoietic stem cell transplantation. Leuk Lymphoma 2004;45:135-137.